Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that it will formally launch and showcase its new Celase® GMP enzyme at the 2015 International Society for Cellular Therapy (ISCT) annual meeting on May 27th to 30th in Las Vegas. This will mark the first time that Cytori has made Celase® GMP available for purchase as a standalone product.
Celase® is a proprietary enzyme blend that was designed specifically to optimize Cytori’s automated adipose tissue dissociation process. Celase® is produced using avian and mammalian tissue-free raw materials, aseptic processes and sterile filtration under cGMP guidelines.
“Celase® GMP’s unique, best-in-class formulation is the result of significant investment made by Cytori,” said Dr. Marc Hedrick, President and CEO of Cytori Therapeutics. “By making Celase® GMP broadly available to researchers, we believe Cytori can simultaneously accelerate the cell therapy field, de-risk clinical implementation and enhance our cash flows. This represents a clear win-win scenario for all parties.”
Integrating Celase® GMP into cell isolation study protocols can facilitate a smooth transition from bench and animal research to downstream clinical applications. Celase® has been approved by the U.S. FDA for use in clinical trials evaluating Cytori Cell Therapy™ in patients with chronic heart failure, osteoarthritis of the knee and hand manifestations of scleroderma.
“Each day our goal is to deliver the best possible health care to our patients. Using a clinical grade enzyme such as Celase® to generate a safe and high quality cell output to treat patients helps us attain this goal,” said Dr. Maurizio Calcagni, Vice Chairman of the Division of Plastic Surgery and Hand Surgery at University Hospital Zurich.
“Cytori’s new Celase® GMP product will provide researchers with superior and unparalleled convenience in their lab, clarity in their approach, and confidence in their results,” said Russ Havranek, Director of Global Marketing and Sales at Cytori Therapeutics.
ISCT attendees are invited to meet with Cytori representatives at booth #901 to learn more about Celase® GMP. Researchers may also visit www.celase.com to be informed of announcements and special offers or send inquiries to [email protected]about purchasing Celase® GMP directly. (Original Source)
Shares of Cytori Therapeutics closed yesterday at $1.24 . CYTX has a 1-year high of $3.01 and a 1-year low of $0.36. The stock’s 50-day moving average is $0.89 and it’s 200-day moving average is $0.65.
On the ratings front, Cytori Therapeutics (NASDAQ: CYTX) has been the subject of a number of recent research reports. In a report issued on March 13, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on CYTX, with a price target of $6, which represents a potential upside of 383.9% from where the stock is currently trading. Separately, on February 19, Maxim Group’s Jason Kolbert reiterated a Buy rating on the stock and has a price target of $7.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Joseph Pantginis and Jason Kolbert have a total average return of 16.9% and 12.9% respectively. Pantginis has a success rate of 59.2% and is ranked #40 out of 3546 while Kolbert has a success rate of 49.6% and is ranked #197
Cytori Therapeutics Inc is engaged in the development of novel treatments for cardiovascular disease and soft tissue injuries and burns.